Cancer Biomarkers Market to Reach $15,737 Million, Globally, by 2022

1. Opportunity Analysis and Industry Forecast, 2016-2023 Cancer Biomarkers Market : Identify Opportunities and Challenges Global Opportunity Analysis and Industry Forecast, 2014-2022

2. Cancer Biomarkers Market “Cancer biomarkers market growth is attributed to the rise in concern for targeted cancer therapies coupled with better companion diagnostic tests for cancer. In many cases, biomarker tests confirm the existence of diseases that can be treated at an early progression stage. In others, the biomarkers can act as a ‐surrogate end point‐ which would help to decide whether a specific therapy is working or not. He further added, Biomarkers are an attractive part of cancer therapy, and novel agents & drugs are prescribed based on a specific target population after understanding the mutation as well as the response rate, which is anticipated to create huge opportunities for the growth of cancer biomarkers industry.”  

3. Cancer Biomarkers Market Overview Cancer Biomarkers Market Report, published by Allied Market Research, forecasts that the global market is projected to reach $15,737 million by 2022 from $6,521 in 2015, growing at a CAGR of 13% from 2016 to 2022. Omic technologies segment accounted for more than half of the revenue share in 2015 and is expected to maintain its dominance during the forecast period. Europe and Asia-Pacific together accounted for more than half of the market share in 2015. Read full summary of the report at: https://www.alliedmarketresearch.com/cancer-biomarkers-market The market for cancer biomarkers is primarily driven by rise in prevalence of cancer cases, growing importance of biological & targeted drug therapies, technological advancements, and accuracy & reliability of cancer biomarkers for cancer detection. Moreover, rise in investments from government, public & private sector for biomarker research and technological advancements for cancer diagnostics have a positive impact on the market. 

4. Cancer Biomarkers Market The need for cancer biomarkers is expected to increase globally during the forecast period majorly due to the alarming prevalence of cancer cases. However, reluctance in adoption of new technologies, high cost of biomarker techniques, and low detection rate are anticipated to restrain the market growth. Moreover, increasing positive effects of the drivers is likely to reveal new market opportunities for the key players. Geographically, the global cancer biomarkers market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the leading revenue generating region, due to high incidence rate of cancer, growth in awareness towards cancer and higher cancer biomarker testing, whereas Asia-Pacific is growing at the fastest CAGR due to increasing disposable incomes, increasing awareness, and rising affordability for advanced cancer treatments. 

5. Cancer Biomarkers Market Snapshot Cancer is highly prevalent in lower and middle income countries as they lack suitable healthcare infrastructure to effectively combat the condition. In the year 2012, WHO estimated that 57% of new cancer cases and 48% of five year prevalent cases occurred in developing or under-developed regions. In addition, the cancer cases were 25% higher in men than in women.  Major companies have adopted collaboration and partnership as their key development strategy. The key players of the cancer biomarkers industry include F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V. and Genomic Health, Inc. The other players in the value chain include: bioMérieux, Astellas Pharma Inc., Myriad Genetics, Epigenomics and Radient Pharmaceuticals.

6. Key Findings of the Cancer Biomarkers Market • Immunoassays are projected to be the fastest growing segment, growing at a CAGR of 18% during the forecast period. • Omic technologies is anticipated to be the highest revenue generating segment followed by imaging technologies during 20162022. • In the year 2015, genetic biomarkers was the leading segment and is projected to grow at a CAGR of 13%. • Use of protein biomarkers was highest in North America, covering approximately 37% of the global market share in 2015. • Europe accounted for approximately one-third of the global cancer biomarkers market in 2015. • Asia-Pacific is estimated to be the fastest growing region in cancer biomarkers market, growing at a CAGR of 14%. • Mexico is projected to be the fastest growing country in the North America region growing at a CAGR of 13% during the forecast period. • China and Japan were the leading markets for cancer biomarkers in the Asia-Pacific region covering three-fifth of the total market in 2015.

7. Cancer Biomarkers Market North America Europe Asia-Pacific LAMEA

8. Cancer Biomarkers Market Thank You! For More Details Visit us at https://www.alliedmarketresearch.com/request-sample/1443 Follow Us On